Synthetic DNA is DNA assembled from scratch in a laboratory, and it is the raw material underneath the entire “DNA as software” thesis that Adam O’Dell builds his Imperium pitch around. To understand the pitch, you first have to understand what this stuff is, how it gets made, and what it costs to order. The short version: it is the difference between copying a document and writing one.
What Synthetic DNA Is
There are two ways to get a strand of DNA. Natural DNA is copied from a living organism, extracted and replicated. Synthetic DNA is written to a customer’s specification, base pair by base pair, to match whatever sequence the customer wants. That difference matters. Copying DNA tells you what already exists. Writing DNA lets you build something that never existed before, which is the whole point of the “software problem” framing.
How It Is Made
The modern way to write synthetic DNA is to assemble it chemically, and the company most associated with that in the Imperium pitch is Twist Bioscience. Twist synthesizes DNA on silicon chips using its NanoWell technology, and the presentation claims this “processes DNA at 10,000 times the speed of the previous technology.” Our analysis could not independently verify that 10,000-times figure, which reads as a marketing number, but the underlying trend is genuine: DNA writing has gotten faster and cheaper year after year.
What It Costs to Order
Prices have fallen sharply over the past two decades. Custom DNA that once cost a meaningful amount per base pair has dropped in price by orders of magnitude, following a curve that loosely mirrors Moore’s law. The effect is that experiments that were once too expensive to run are now routine, and the falling cost is the quiet engine behind the entire synthetic-biology field.
The Software Metaphor
O’Dell’s framing turns this into an investment thesis. “Once you can read, design, and write the code of living things,” the pitch runs, “every industry that sells an animal, a plant, a fiber, or a molecule is suddenly just a software problem.” The idea is that the write step, synthetic DNA, is the same kind of platform the silicon chip was for computing. Twist Bioscience plays the Intel role in that story, and its financials back a real business: 15 consecutive quarters of roughly 20% revenue growth and a market cap near $7.6 billion. You can read the fuller company story in our Twist Bioscience stock explainer.
Why It Matters
O’Dell is not a stranger to spotting these platform shifts early. He began teasing Palantir in the spring of 2024 when the stock was in the $20s, and it became the best-performing stock in the S&P 500 for the year. Synthetic DNA is a slower, more speculative bet than that, but the building block itself is real and improving. If you want to go deeper into how the chemistry works, see our DNA synthesis explainer, and for the difference between short and whole-gene synthesis, our gene synthesis explainer covers it.
Where It Gets Used
Synthetic DNA is the common input across a long list of applications. Drug companies order custom sequences to discover and test new medicines. Diagnostic makers build DNA probes that detect specific genetic signatures. Researchers use it to edit genes and study how they work. The same write step also underpins longer-shot ideas like DNA data storage. What ties them together is that they all start with the same raw material: a sequence written to order.
The Stack It Feeds
In the Imperium framing, synthetic DNA is the base of a three-layer stack. Twist Bioscience writes it, playing the Intel role. Ginkgo Bioworks, the “Microsoft” layer, builds the software and robotic labs that run experiments on top. Absci sits at the apps layer with a baldness and endometriosis drug, ABS-201, backed by an Eli Lilly stake. The “We’re Intel, they’re Microsoft” line, originally a Twist CEO quote from 2015, sketches how the layers divide the work.
The Presenter and the Offer
O’Dell is the chief investment strategist at Money & Markets and the founder of Green Zone Fortunes, and he also runs Cycle 9 Alert and 10X Profits. His method leans on the Green Zone Power Ratings, a quantitative screen that scores stocks on momentum, value, and volatility. The pitch itself is “Imperium: The No. 1 Investment for 2027,” $297 a year with a 30-day refund, and it teases Twist around $112, Ginkgo around $8.32, and Absci around $7.58.
The Honest Caveat
The one number to treat carefully is the “10,000 times faster” claim. Our analysis could not independently verify it, and it reads as a marketing number. What we can verify is the direction: synthetic DNA has gotten dramatically cheaper over the past two decades, and that cost curve, not any single speed figure, is the real story underneath the pitch.
Why the Timing Matters
O’Dell’s argument is that synthetic DNA is at a tipping point, the moment where a technology goes from lab curiosity to industrial input. His credibility on such calls is part of why the pitch deserves attention. He began teasing Palantir in the spring of 2024 in the $20s, and it became the best-performing stock in the S&P 500 for the year. Synthetic DNA is a slower, more speculative arc than a software company, but the building block itself is real and improving.
Ready to see the research? Click here to access Adam O’Dell’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.